ArticleUnited European gastroenterology journal2024
Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management.
Article in United European gastroenterology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of New Media-Based Education on the Treatment of Helicobacter pylori Infection: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2025Pooled it
- Efficacy of fourteen-day once-daily vonoprazan-based quadruple therapy for Helicobacter pylori in high clarithromycin-resistance regions (ONCE-VONO Trial).Scientific reports · 2025Trial
- Bismuth-Based quintuple therapy: a step beyond quadruple regimens in H. Pylori treatment and the impact of patient compliance.BMC gastroenterology · 2025Trial
- Review
- Factors related to loss to follow-up and low compliance in Helicobacter pylori-infected children: The EuroPedHp Registry.Journal of pediatric gastroenterology and nutrition · 2026Observational
- From Eradication to Holistic Regeneration: Pharmaceutics Strategies for Reshaping Gastric Homeostasis AgainstPharmaceutics · 2026Review
- Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.Alimentary pharmacology & therapeutics · 2026Review
- European Code Against Cancer, 5th edition - cancer-causing infections and related interventions.Molecular oncology · 2026Review
- Diagnosis, Treatment Patterns and Eradication Success forJGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Tailored Therapy vs. Empirical Therapy forJournal of personalized medicine · 2025Review
- Novel chromogenic medium-based method for the rapid detection ofWorld journal of gastroenterology · 2025Article
- First-Line Prescriptions and Effectiveness ofAntibiotics (Basel, Switzerland) · 2025Article
- Biomaterials mediated 3R (remove-remodel-repair) strategy: holistic management of Helicobacter pylori infection.Journal of nanobiotechnology · 2025Review
- Antibiotic Resistance and Genetic Determinants ofInternational journal of molecular sciences · 2025Article
- Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker- and Proton Pump Inhibitor-Based Bismuth Quadruple Therapy forGastro hep advances · 2025Review
- Newer Therapies for RefractoryAntibiotics (Basel, Switzerland) · 2024Review
- Role of probiotics in preventing adverse events related to Helicobacter pylori treatment.United European gastroenterology journal · 2024Article
- Prevalence ofLife (Basel, Switzerland) · 2024Article
- Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management.United European gastroenterology journal · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors.
Funding
Abstract
backgroundAdherence to Helicobacter pylori (H. pylori) eradication treatment is a cornerstone for achieving adequate treatment efficacy.
objectiveTo determine which factors influence compliance with treatment.
methodsA systematic prospective non-interventional registry (Hp-EuReg) of the clinical practice of European gastroenterologists. Compliance was considered adequate if ≥90% drug intake. Data were collected until September 2021 using the AEG-REDCap e-CRF and were subjected to quality control. Modified intention-to-treat analyses were performed. Multivariate analysis carried out the factors associated with the effectiveness of treatment and compliance.
resultsCompliance was inadequate in 646 (1.7%) of 38,698 patients. The non-compliance rate was higher in patients prescribed longer regimens (10-, 14-days) and rescue treatments, patients with uninvestigated dyspepsia/functional dyspepsia, and patients reporting adverse effects. Prevalence of non-adherence was lower for first-line treatment than for rescue treatment (1.5% vs. 2.2%; p < 0.001). Differences in non-adherence in the three most frequent first-line treatments were shown: 1.1% with proton pump inhibitor + clarithromycin + amoxicillin; 2.3% with proton pump inhibitor clarithromycin amoxicillin metronidazole; and 1.8% with bismuth quadruple therapy. These treatments were significantly more effective in compliant than in non-compliant patients: 86% versus 44%, 90% versus 71%, and 93% versus 64%, respectively (p < 0.001). In the multivariate analysis, the variable most significantly associated with higher effectiveness was adequate compliance (odds ratio, 6.3 [95%CI, 5.2-7.7]; p < 0.001).
conclusionsCompliance with Helicobacter pylori eradication treatment is very good. Factors associated with poor compliance include uninvestigated/functional dyspepsia, rescue-treatment, prolonged treatment regimens, the presence of adverse events, and the use of non-bismuth sequential and concomitant treatment. Adequate treatment compliance was the variable most closely associated with successful eradication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.